These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12600650)

  • 21. Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
    de Vries-Sluijs TE; van der Eijk AA; Hansen BE; Osterhaus AD; de Man RA; van der Ende ME
    J Clin Virol; 2006 May; 36(1):60-3. PubMed ID: 16418013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Failure of combination therapy with lamivudine and famciclovir following lamivudine monotherapy for hepatitis B virus infection in patients coinfected with human immunodeficiency virus-1.
    Matthews GV; Pillay D; Cane P; Ratcliffe D; Gazzard B; Nelson M
    Clin Infect Dis; 2001 Dec; 33(12):2049-54. PubMed ID: 11698987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of human immunodeficiency virus on viral hepatitis.
    Mallet V; Vallet-Pichard A; Pol S
    Liver Int; 2011 Jan; 31 Suppl 1():135-9. PubMed ID: 21205151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
    Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
    Archampong TN; Boyce CL; Lartey M; Sagoe KW; Obo-Akwa A; Kenu E; Blackard JT; Kwara A
    Antivir Ther; 2017; 22(1):13-20. PubMed ID: 27167598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations.
    Sucupira MV; Mello FC; Santos EA; Niel C; Rolla VC; Arabe J; Gomes SA
    Mem Inst Oswaldo Cruz; 2006 Sep; 101(6):655-60. PubMed ID: 17072479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
    Sheldon J; Camino N; Rodés B; Bartholomeusz A; Kuiper M; Tacke F; Núñez M; Mauss S; Lutz T; Klausen G; Locarnini S; Soriano V
    Antivir Ther; 2005; 10(6):727-34. PubMed ID: 16218172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiency virus/hepatitis B virus co-infected patients in Brazil.
    Silva AC; Spina AM; Lemos MF; Oba IT; Guastini Cde F; Gomes-Gouvêa MS; Pinho JR; Mendes-Correa MC
    Mem Inst Oswaldo Cruz; 2010 Sep; 105(6):770-8. PubMed ID: 20944991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.
    Delaney WE; Locarnini S; Shaw T
    Antivir Chem Chemother; 2001 Jan; 12(1):1-35. PubMed ID: 11437320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Occult hepatitis B infection in patients infected with HIV: report of two cases of hepatitis B reactivation and prevalence in a hospital cohort.
    Bloquel B; Jeulin H; Burty C; Letranchant L; Rabaud C; Venard V
    J Med Virol; 2010 Feb; 82(2):206-12. PubMed ID: 20029819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.
    Kouanfack C; Aghokeng AF; Mondain AM; Bourgeois A; Kenfack A; Mpoudi-Ngolé E; Ducos J; Delaporte E; Laurent C
    Antivir Ther; 2012; 17(2):321-6. PubMed ID: 22290198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
    J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
    Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ
    Hepatology; 2008 Oct; 48(4):1062-9. PubMed ID: 18697216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of hepatitis B in patients coinfected with the human immunodeficiency virus.
    Lessells R; Leen C
    Eur J Clin Microbiol Infect Dis; 2004 May; 23(5):366-74. PubMed ID: 15112069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B virus infection: co-infection with hepatitis C virus, hepatitis D virus, and human immunodeficiency virus.
    Shukla NB; Poles MA
    Clin Liver Dis; 2004 May; 8(2):445-60, viii. PubMed ID: 15481349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
    Jain MK; Comanor L; White C; Kipnis P; Elkin C; Leung K; Ocampo A; Attar N; Keiser P; Lee WM
    J Viral Hepat; 2007 Mar; 14(3):176-82. PubMed ID: 17305883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of hepatitis B virus infection on HIV response to antiretroviral therapy in a Chinese antiretroviral therapy center.
    Yang R; Gui X; Xiong Y; Gao SC; Yan Y
    Int J Infect Dis; 2014 Nov; 28():29-34. PubMed ID: 25236390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
    Núñez M; Ramos B; Díaz-Pollán B; Camino N; Martín-Carbonero L; Barreiro P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Sep; 22(9):842-8. PubMed ID: 16989608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
    Bihl F; Martinetti G; Wandeler G; Weber R; Ledergeber B; Calmy A; Battegay M; Cavassini M; Vernazza P; Caminada AP; Rickenbach M; Bernasconi E;
    BMC Gastroenterol; 2015 Jul; 15():79. PubMed ID: 26152237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The burden of hepatitis B virus (HBV) infection, genotypes and drug resistance mutations in human immunodeficiency virus-positive patients in Northwest Ethiopia.
    Deressa T; Damtie D; Fonseca K; Gao S; Abate E; Alemu S; Aleka Y; Swain MG; van Marle G; Coffin CS
    PLoS One; 2017; 12(12):e0190149. PubMed ID: 29281718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.